A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats  by Arumugam, Thiruma V. et al.
Kidney International, Vol. 63 (2003), pp. 134–142
A small molecule C5a receptor antagonist protects kidneys
from ischemia/reperfusion injury in rats
THIRUMA V. ARUMUGAM, IAN A. SHIELS, ANNA J. STRACHAN, GIOVANI ABBENANTE,
DAVID P. FAIRLIE, and STEPHEN M. TAYLOR
Department of Physiology and Pharmacology, School of Biomedical Sciences, and Centre for Drug Design and
Development, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia
A small molecule C5a receptor antagonist protects kidneys Renal ischemia/reperfusion (I/R) injury is a significant
from ischemia/reperfusion injury in rats. complication of vascular surgery of the aorta and kidney.
Background. C5a has been implicated in numerous patho- It also commonly occurs when renal perfusion is reducedphysiological conditions, including ischemia/reperfusion (I/R)
during shock, and I/R-induced renal failure remains a ma-injury of the kidney. We examined whether a novel and specific
jor cause of morbidity and mortality in hospitalized pa-C5a receptor antagonist, the cyclic compound AcF-[OPdChaWR]
could moderate I/R-induced renal injury in rats. tients [1]. There is currently no effective therapy to pre-
Methods. Female Wistar rats were subjected to renal ischemia vent cellular injury resulting from renal I/R [2]. Although
(60 min) and reperfusion (5 h). Rats were treated with either there is continuing debate about the nature of the media-1 mg/kg IV in 5% ethanol/saline or 10 mg/kg PO in 25% ethanol/
tors of renal I/R, numerous studies have identified thesaline prior to ischemia. I/R injury was characterized by signifi-
following inflammatory mediators as likely being involved:cant tissue hemorrhage with increased microvascular perme-
ability, elevated renal tissue levels of tumor necrosis factor- oxygen-derived reactive species [3], tumor necrosis fac-
(TNF-) and myeloperoxidase (MPO), increased serum levels tor- (TNF-) [1, 4], phospholipase A2 (PLA2) [5], leuko-of creatinine and aspartate aminotransferase (AST) and hema-
triene B4 (LTB4) [6], intercellular adhesion molecule-1turia.
(ICAM-1) [7, 8], P-selectin [9], polymorphonuclear leuko-Results. Pre-ischemic treatment with the C5a receptor (C5aR)
antagonist (1 mg/kg IV or 10 mg/kg PO) substantially inhibited cytes (PMNs) [10] and platelet-activating factor (PAF) [11].
or prevented I/R-induced hematuria, vascular leakage, tissue Polymorphonuclear leukocytes play an important role
levels of TNF- and MPO, and serum levels of AST and creati- in mediating the tissue injury associated with I/R injuries,
nine. Histological examination of kidneys from antagonist pre-
accumulating in tissues during ischemia, and this is exacer-treated I/R animals showed a marked reduction in tissue dam-
bated by reperfusion [12]. PMN activation has been dem-age compared to drug-free I/R rats. This antagonist, however,
did not inhibit complement-mediated lysis of red blood cells, onstrated in renal I/R [13, 14], which is seen as adherence
suggesting unimpaired formation of the membrane attack com- of leukocytes to vascular endothelium, retention of PMNs
plex (MAC). in the affected tissue, and release of myeloperoxidaseConclusions. The results demonstrate for the first time that
(MPO). ICAM-1 and P-selectin, which facilitate the ad-a selective antagonist of both human and rat C5a receptors,
hesion of PMNs to the vascular endothelium, are impor-given either intravenously or orally, significantly protects the
kidney from I/R injury in the rat. We conclude that C5a is an tant in the pathology of renal I/R. ICAM-1 deficiency
important pathogenic agent in renal I/R injury, and that C5a [7], treatment with antibodies against ICAM-1 [8], or
receptor antagonists may be useful therapeutic agents for the P-selectin blockade [9] reduce renal I/R injury.pretreatment of anticipated renal reperfusion injury in humans.
Some experimental studies have shown that I/R injury
results in local tissue production of the complement fac-
tor 5a (C5a) [15, 16]. C5a involvement in I/R injury has
been demonstrated by the use of a variety of agents that
blocked the action of C5a and reduced I/R-induced injury
[17–20]. However, the effects of a specific C5a receptor
Key words: acute renal ischemia-reperfusion, C5a receptor antagonist,
(C5aR) antagonist have not been determined in renal I/RAcF-[OPdChaWR], polymorphonuclear leukocytes, transplantation,
organ storage. injury to date. Activation of C5a receptors on PMNs leads
to chemotaxis, expression of cellular adhesion receptors,Received for publication June 6, 2002
and release of pro-inflammatory mediators [21, 22]. Theand in revised form August 6, 2002
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prevent the activation and extravasation of PMNs may mm O.D.) was inserted into the femoral vein to allow the
infusion of either 1 mg/kg AcF-[OPdChaWR] (1 mg/mLbe therapeutic for the prevention or treatment of I/R.
The purpose of the present study, therefore, was to stock solution; 5% ethanol in endotoxin-free saline) over
a two-minute period 15 minutes prior to occlusion of thedetermine the effects of a new, potent and selective C5aR
antagonist, AcF-[OPdChaWR] (AcPhe[Orn-Pro-D-cyclo- renal blood vessels. Oral dosing of AcF-[OPdChaWR]
(10 mg/kg) was achieved by gavage (10 mg/mL stock solu-hexylalanine-Trp-Arg]) [23], against renal I/R injury in
rats. This cyclic antagonist is orally active [18, 24, 25], tion in 25% ethanol/saline) 60 minutes prior to occlusion.
Rats in the sham-operated and I/R injury groups werean effective inhibitor of gut I/R injury [18], endotoxin-
induced hypotension and neutropenia [26], and the re- infused with 0.2 mL of 5% ethanol in saline or gavaged
with 0.2 mL of 25% ethanol in saline at the same rate asverse-passive Arthus reaction [24, 27]. In the present study,
we demonstrate that either intravenous or oral adminis- drug treated groups. The left renal pedicle was exposed
through a midline abdominal incision and a polyethylenetration of the antagonist is effective in inhibiting both
biochemical and tissue changes that occur in a rat model catheter (0.8 mm O.D.) was inserted into the left ureter
to collect urine from the occluded kidney. Renal ischemiaof renal I/R injury, suggesting that C5a is a major patho-
genic mediator of this condition in rats. was induced by clamping the pedicle with a non-trau-
matic occlusive device (Yasergil aneurysm clamp; Jarit
Instruments, Sydney, Australia). After 60 minutes of oc-
METHODS
clusion the clamp was removed and the animal was moni-
Antagonist preparation tored for a further five hours of reperfusion. We used a
similar surgical and experimental procedure as previouslyThe C5aR antagonist, the cyclic molecule AcF-[OPd-
ChaWR], was synthesized as previously described [23, 28]. reported [4]. Sham-operated animals underwent an iden-
tical surgical procedure, including isolation of the renalThe compound, as the acetate salt, was purified by re-
versed-phase high-pressure liquid chromatography (HPLC) pedicle, but occlusion of the pedicle was not performed.
At the end of the five-hour reperfusion period, wholeand fully characterized by mass spectrometry and proton
nuclear magnetic resonance (NMR) spectroscopy as re- blood was collected into heparinized Eppendorf tubes
and plasma samples collected and stored at 20C forported [23, 28].
later measurement of plasma aspartate aminotransferase
Red blood cell lysis assay (AST) and creatinine. The animals were then euthanized
with an overdose of pentobarbital. The left and rightTo determine whether AcF-[OPdChaWR] inhibited
activation of the complement cascade and formation of kidneys were removed and immediately fixed in 10%
buffered formaldehyde-saline for histological studies.the terminal membrane attack complex (MAC), a red
blood cell lysis assay was used as previously described
Measurement of biochemical parameters[29]. Sheep erythrocytes were sensitized with hemolysin
and incubated with dilutions of human serum. A serum Plasma concentrations of creatinine were measured as
indicators of impaired glomerular function [30]. Plasmadilution (1/100) causing approximately 70% hemolysis
(determined spectrophotometrically at 415 nmol/L) was concentrations of AST, an enzyme that occurs in the
proximal tubule cells, were measured as an indicator ofused to assay inhibitory activity of AcF-[OPdChaWR]
and a control inhibitor, rosmarinic acid [29]. AcF-[OPd- renal parenchymal cell injury [31, 32]. AST and creati-
nine concentrations were measured within 48 hours ofChaWR] or rosmarinic acid were preincubated with se-
rum for 10 minutes at 37C prior to addition of sensitized collecting plasma. Concentrations were derived from cali-
bration curves. AST results are expressed as Sigma-Frankeerythrocytes. Results were expressed as a percentage of
the maximal red blood cell lysis that occurred in the (SF) U/mL. Creatinine results are expressed as mol/L.
presence of distilled water. Data are shown as the %
Measurement of leukocytes in the urinemean  SEM maximum lysis for each experiment.
Urine samples from the ureters of occluded kidneys
Model of renal ischemia/reperfusion injury and sham-operated kidneys were collected at the end
of the reperfusion period and leukocytes counts wereFemale Wistar rats (250 to 300 g) were fasted and given
water only for 12 hours prior to all experiments. Animals performed using a hemocytometer. Leukocytes counts
were expressed as cells/L urine.were anesthetized by intraperitoneal injection of zola-
zepam (25 mg/kg1), tiletamine (25 mg/kg1) and xyla-
Determination of renal microvascular permeabilityzine (10 mg kg1), and anesthesia was maintained by
administration of a single dose of 80 mg/kg ketamine In a separate series of identical experiments, renal vas-
cular permeability was assessed by measuring the extrava-and 10 mg/kg xylazine during the procedure. During the
procedure rats were placed on a heating pad to maintain sation of Evans blue (EB) dye into the renal tissues. EB
(1% solution of EB in saline injected at 2.5 mL/kg) wasnormal body temperature. A polyethylene catheter (0.5
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injected into the femoral vein catheter 60 minutes prior
to the end of reperfusion period. At the end of the experi-
ment anesthetized animals were killed by exsanguination
from the thoracic aorta. The kidneys were excised, dried
at 80C for 12 hours and weighed. The kidneys were
incubated in 2 mL formamide for 24 hours and the con-
centration of EB dye in the formamide extract deter-
mined by spectrophotometry at a wavelength of 620 nm.
Tissue concentrations of EB were determined from a
standard curve. The EB dye concentration for each sam-
ple was expressed as g/g kidney tissue.
Measurement of renal levels of TNF-
In another set of experiments, kidneys were removed
at the end of the reperfusion period, blotted dry and
weighed, then homogenized in 10 mmol/L phosphate
buffer (pH 7.4) containing 0.05% (wt/vol) of sodium
azide at 4C. Homogenates were then sonicated for 20
seconds and centrifuged (10,000  g for 10 min). The
supernatants were stored at 20C until analysis. Renal
concentrations of TNF- were measured using an en-
zyme-linked immunosorbent assay (ELISA; OptEIA;
Pharmingen, San Diego, CA, USA), according to the
manufacturer’s instructions. Concentrations of TNF- in Fig. 1. Plasma concentrations of creatinine and aspartate aminotrans-
ferase (AST) after renal ischemia/reperfusion (I/R) injury. Renal I/Rsupernatant were determined by linear regression analy-
caused significant elevation of both plasma creatinine (A) and ASTsis from the standard curve.
concentrations (B) compared with sham-operated animals. Rats pre-
treated with the C5aR antagonist AcF-[OPdChaWR] either 1 mg/kg
Determination of renal MPO activity IV or 10 mg/kg PO showed a significant reduction in plasma creatinine
or AST compared to I/R animals. Data are shown as means  SEMThe technique for measuring renal MPO activity was
(N  6 to 15 in each group). Symbols are: () Sham; ( ) Sham  1a modification of the technique previously described [33]. mg/kg IV AcF-[OPdChaWR]; () I/R injury; ( ) I/R 1 mg/kg IV
At the end of the reperfusion period, the kidneys were AcF-[OPdChaWR]; ( ) I/R  10mg/kg PO AcF-[OPdChaWR]. *P 	
0.001 vs. sham-operated animals; P 	 0.001 vs. I/R animals.removed, weighed, homogenized with 10 mmol/L phos-
phate buffer (pH 7.4) and then sonicated for 20 seconds.
After centrifugation (10,000  g for 10 min), 5 L of
supernatant was added to 195 L of 10 mmol/L phos- Statistical analysis
phate buffer (pH 6.0). Substrate solution containing
All experimental results are expressed as mean  the2.85 mg/mL o-dianisidine and 0.025% hydrogen perox-
standard error of the mean (SEM). Data analysis waside was added to the diluted supernatant. After five min-
performed using GraphPad Prism 3.0 software (Graph-utes, the absorbance at 460 nm was measured with a
Pad Software, Inc., San Diego, CA, USA). Statistical com-spectrophotometer. MPO activity of the supernatant was
parisons were made using analysis of variance (ANOVA)expressed as the optical density/g kidney tissue.
followed by Newman-Keuls comparison test analysis, and
Renal histopathology statistical significance was assessed at P 	 0.001.
The fixed kidneys were embedded in paraffin, sec-
tioned (5 m), and stained with hematoxylin and eosin RESULTS
(H&E). Sections were examined in a blinded fashion
Plasma markersand the degree of damage was scored between 0 and 4. A
Animals incurring renal I/R injury exhibited signifi-score of 0 was assigned to tissues with no visible damage.
cant increase in the plasma concentrations of creatinineKidneys showing lesions of mild hemorrhage as the only
and AST compared to uninjured, sham-operated animalspathological change were scored 1. A score of 2 was
(Fig. 1). After five hours of reperfusion, the plasma levelgiven to kidneys that showed hemorrhage and mild
of creatinine (Fig. 1A) had increased from 41.8  1.5changes, like protein casts, in the renal tubules. Kidneys
mol/L (sham-operated) to 129.6  16.5 mol/L (N with moderate hemorrhage and more severe tubular pa-
10, P 	 0.001). In animals pre-treated with the C5aRthology were scored 3, while a score of 4 was reserved
antagonist, the elevation in plasma creatinine after reper-for kidneys with severe hemorrhage, marked peritubular
edema and visible evidence of renal tubular necrosis. fusion was significantly less than I/R animals. Pre-treat-
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Fig. 2. Renal I/R induced urinary leukocytes. Renal I/R caused a sig- Fig. 3. Renal I/R-induced microvascular permeability measured by
nificant increase in urine leukocyte counts compared with sham-oper- Evans blue extravasation. Rats with I/R showed a significant increase
ated animals, which had no detectable leukocytes in the urine. Pretreat- in Evans blue leakage compared with sham-operated animals. Pretreat-
ment of rats with the C5aR antagonist AcF-[OPdChaWR] with either ment of rats with the C5aR antagonist AcF-[OPdChaWR] either 1
1 mg/kg IV or 10 mg/kg PO blocked I/R-induced urinary leukocytes. mg/kg IV or 10 mg/kg PO significantly reduced Evans blue leakage
Data are shown as means  SEM (N  4 to 6 in each group). Symbols compared to I/R animals. Data are shown as means  SEM (N  6 to
are: () Sham; ( ) Sham  1 mg/kg IV AcF-[OPdChaWR]; () I/R 9 in each group). Symbols are: () Sham; ( ) Sham 1 mg/kg IV AcF-
injury; ( ) I/R  1 mg/kg IV AcF-[OPdChaWR]; ( ) I/R  10 mg/kg [OPdChaWR]; () I/R injury; ( ) I/R1 mg/kg IV AcF-[OPdChaWR];
PO AcF-[OPdChaWR]. *P 	 0.001 vs. sham-operated animals, P 	 ( ) I/R  10 mg/kg PO AcF-[OPdChaWR]. *P 	 0.001 vs. sham-
0.001 vs. I/R animals. operated animals, P 	 0.001 vs. I/R animals.
ment with C5aR antagonist at either 1 mg/kg IV or Renal microvascular permeability
10 mg/kg PO resulted in plasma creatinine concentra- Renal vascular permeability, as assessed by tissue lev-
tions of 83.2 6.4 mol/L (P	 0.001, N 6) and 83.9 els of Evans blue dye, was significantly higher in rats
6.5 mol/L (P 	 0.001, N  6), respectively. with I/R (115  18 g/g tissue, P 	 0.001) than in sham-
Plasma AST concentrations (Fig. 1B) increased sig- operated rats (60  5 g/g tissue, P 	 0.001; Fig. 3).
nificantly with I/R from 73.1 14.4 U/mL in sham oper- Administration of the C5aR antagonist (1 mg/kg IV and
ated to 790.7 166.8 U/mL in I/R animals (N  15, P 	 10 mg/kg PO) significantly inhibited the increases in re-
0.001). Pre-treatment with either 1 mg/kg IV or 10 mg/kg nal vascular permeability after I/R (76  2 g/g tissue
and 76  6 g/g tissue; N  6 to 9, P 	 0.001, respec-PO of the C5aR antagonist significantly reduced the in-
tively). Pretreatment of sham-operated rats with 1 mg/kgcrease in plasma AST levels to 129.1  18.3 U/mL (N 
IV C5aR antagonist only did not affect microvascular8, P 	 0.001) and 86.2  4.3 U/mL (N  6, P 	 0.001),
permeability compared to sham-operated animals (Fig. 3).respectively, compared to control I/R animals. Pretreat-
ment of sham-operated rats with 1 mg/kg IV C5aR antag-
Renal tissue MPO and TNF- activityonist only did not affect plasma AST or creatinine levels.
Administration of the C5aR antagonist significantly
inhibited the I/R-induced increases in renal tissue levelsUrinary leukocyte counts
of TNF- and MPO. The concentration of TNF- inIschemia/reperfusion injury caused both erythrocytes
kidneys from rats subjected to renal I/R increased fromand leukocytes to appear in the urine. Owing to extensive
206  12 pg/g tissue in sham-operated animals to 618 red blood cell lysis, no attempt was made to count the
134 pg/g tissue (N  6, P 	 0.001; Fig. 4). Renal tissueerythrocytes in the urine. Animals with renal I/R injury
levels of TNF- were significantly lower in rats pre-
had numerous leukocytes (671  123 cells/L, N  6,
treated with 1 mg/kg IV C5aR antagonist (171 14 pg/g
P 	 0.001) in the urine, whereas sham-operated animals tissue; N  4, P 	 0.001) or 10 mg/kg PO (130  7 pg/g
or sham-operated rats with 1 mg/kg IV C5aR antagonist tissue; N  5, P 	 0.001).
had no detectable urinary leukocytes (Fig. 2). Cells in Renal tissue MPO also increased from 1.17 0.1 OD/g
the urine consisted of approximately 70% lymphocytes tissue in sham-operated animals to 4.6 0.9 OD/g tissue
and 20% neutrophils. The proportions of leukocytes seen after reperfusion (N  10, P 	 0.001; Fig. 5). The I/R-
in the urine suggest that they derived from leakage of induced increases in renal levels of MPO optical density
blood into the tubule. Animals pre-treated with 1 mg/kg were significantly lower in rats pretreated with the C5aR
IV C5aR antagonist only (N  4) had no detectable uri- antagonist at 1 mg/kg IV (2.2  0.2 OD/g tissue; N 
nary erythrocytes or leukocytes. Pre-treatment with 10 8, P 	 0.001) and 10 mg/kg PO (2.1  0.3 OD/g tissue;
mg/kg PO C5aR antagonist significantly reduced to very N  5, P 	 0.001). Pretreatment of sham-operated rats
low levels, but did not completely abolish urinary leuko- with 1 mg/kg IV C5aR antagonist only did not affect
tissue TNF- or MPO levels (Figs. 4 and 5).cytes (24  11 cells /L; N  5, P 	 0.001).
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Fig. 4. Renal I/R induced tissue TNF-. Renal I/R resulted in signifi-
cant elevation in tissue TNF- compared with sham-operated animals.
Rats pretreated with the C5aR antagonist AcF-[OPdChaWR] at either
1 mg/kg IV or 10 mg/kg PO showed inhibition of the elevation of tissue
TNF- levels compared with I/R animals. Data are shown as means 
SEM (N  4 to 6 in each group). Symbols are: () Sham; ( ) Sham 
1 mg/kg IV AcF-[OPdChaWR]; () I/R injury; ( ) I/R  1 mg/kg IV
AcF-[OPdChaWR]; ( ) I/R  10 mg/kg PO AcF-[OPdChaWR]. *P 	
0.001 vs. sham-operated animals, P 	 0.001 vs. I/R animals.
Fig. 6. Histological analysis of I/R-induced renal tissue injury. Micro-
scopic images of renal tissue sections are from (A ) sham, (B ) I/R, (C )
1 mg/kg IV AcF-[OPdChaWR]  I/R, and (D ) 10 mg/kg PO AcF-
[OPdChaWR]  I/R groups. Large arrow indicates hemorrhage in the
renal parenchyma and small arrowheads indicate peritubular edema of
the distal tubules. Sections of 5 m were stained with hematoxylin-
eosin and the original magnification was 200.
Fig. 5. Renal tissue MPO activity. Renal I/R resulted in significant
elevation in tissue MPO activity compared with sham-operated animals.
Rats pretreated with the C5aR antagonist AcF-[OPdChaWR] at either
1 mg/kg IV or 10 mg/kg PO had reduced tissue MPO activity compared
with I/R animals. Data are shown as means  SEM (N  5 to 10 in
each group). Symbols are: () Sham; ( ) Sham  1 mg/kg IV AcF-
[OPdChaWR]; () I/R injury; ( ) I/R  1 mg/kg IV AcF-[OPd-
ChaWR]; ( ) I/R  10 mg/kg PO AcF-[OPdChaWR]. *P 	 0.001 vs. Fig. 7. Numerical score of the degree of pathological change in kidneys.
Renal I/R resulted in damage to the renal tissue compared to sham-sham-operated animals, P 	 0.001 vs. I/R animals.
operated animals. Pretreatment with the C5aR antagonist AcF-[OPd-
ChaWR] at either 1 mg/kg IV or 10 mg/kg reduced renal I/R-induced
tissue damage compared to I/R animals. Data are shown as means 
SEM (N 6 to 10 in each group). Symbols are: () Sham; ( ) ShamHistopathology
1 mg/kg IV AcF-[OPdChaWR]; () I/R injury; ( ) I/R  1 mg/kg IV
Sham-operated animals and drug-treated sham ani- AcF-[OPdChaWR]; ( ) I/R  10 mg/kg PO AcF-[OPdChaWR].
mals had no detectable histological changes in the kid-
neys (Figs. 6A and 7). In animals subjected to renal I/R
the most common lesion was hemorrhage in the renal
tions up to 100 mol/L. This standard hemolytic assayparenchyma. This appeared to be most severe in the zone
for complement activation requires C5b-mediated for-between the cortex and medulla (Fig. 6B). Other detect-
mation of the MAC [29]. In the same assay, a reportedable changes included peritubular edema of the distal
C3/C5 convertase inhibitor, rosmarinic acid, inhibitedtubules and collecting ducts, some tubular casts and in a
red blood cell lysis by approximately 70% at 100 mol/Lfew cases there was also varying degrees of damage to
(Fig. 8). We conclude that the selective C5aR antagonistproximal tubule epithelial cells. The tubule cells had loss
does not impair the formation of the MAC.of nuclei, with the most severely affected cells being in
the distal tubules. Animals that were pretreated with
antagonist had less severe lesions (Figs. 6 C, D and 7).
DISCUSSION
Unimpaired MAC activity The complement system is activated during I/R injury
in a number of organs, including the gut [16, 34], kidneyAcF-[OPdChaWR] did not have any affect on hemoly-
sin-induced lysis of sheep red blood cells in concentra- [35], heart [36], liver [37] and central nervous system [38].
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phils releases cytokines, reactive oxygen species, MPO
and other enzymes [10, 45]. Reperfusion of microvessels
results in the adherence of leukocytes to the endothe-
lium, increased migration of leukocytes to the affected
site, and increased microvascular permeability resulting
in tissue edema [46]. Several studies have demonstrated
that inhibition of neutrophil activation prevented or re-
duced renal I/R mediated injury [7–9]. In rats, leukope-
nia also significantly inhibited the increase in renal vascu-
lar permeability as well as helped to maintain renal tissue
blood flow during renal I/R [33]. In the present study,
neutrophils were not seen prominently in the damaged
parenchyma of mild-to-moderately damaged kidneys.
Fig. 8. Unimpaired MAC activity. Effect of AcF-[OPdChaWR] on The relatively low numbers of neutrophils seen may be
hemolysin-induced RBC lysis. The C5a antagonist AcF-[OPdChaWR]
due in part to the relatively short time course of theat concentrations up to 100mol/L had no effect on RBC lysis. Rosmari-
nic acid (100 mol/L) inhibited RBC lysis by 70%. Symbols are: () experiments. Tissue MPO activity was significantly in-
AcF-[OPdChaWR]; () Rosmarinic acid. creased, however, which may reflect some contribution
by adhering resident macrophages [47], as it has been
reported that there is a lack of correlation between renal
MPO levels and tissue neutrophils after I/R [47].The present study shows that a new C5aR antagonist
The appearance of blood in the urine suggests theinhibits a rat model of renal I/R injury. The drug was
degree of renal damage resulted in tissue hemorrhage andeffective when administered either by intravenous or oral
escape of blood into the urine. We attempted to quantifyroutes. We have recently reported that this antagonist
the escape of blood-borne cells from the plasma to thealso is effective in treating I/R injury of the gastrointesti-
renal tubule and urine, so leukocyte counts were per-nal tract when administered either orally or intravenously
formed because there was almost complete hemolysis of
to rats [18].
erythrocytes in urine. There was extensive hemorrhage
The role of C5a is undergoing increasing scrutiny in
in the kidney parenchyma following I/R. The C5a antag-
renal inflammatory diseases. C5a has been shown to be onist blocked both the appearance of urinary leukocytes
present in thrombotic glomerulonephritis [39], while en- and hemolyzed red blood cells in the urine, as well as
hanced expression of C5aR mRNA has been demon- the hemorrhage caused by I/R. Renal I/R activates the
strated in the human kidney in membranous nephropa- TNF- transcription factor nuclear factor-
B and in-
thy and mesangial proliferative glomerulonephritis [40]. creases TNF- activity in the kidney [1, 4]. Our recent
C5aRs have been identified on human renal proximal tu- in vivo studies showed that pretreatment with C5aR an-
bular cells [41] and in leukocytes in rat renal tissue [42]. tagonists blocked any rise in plasma TNF- levels to
Despite these findings, it is still not clear what role com- either small intestinal I/R injury [18], immune complex-
plement in general, and C5a in particular, play (if any) mediated peritoneal [27] or dermal inflammation [24],
in renal I/R injury, and the present study was carried out or acute administration of lipopolysaccharide [26]. These
with a specific C5a receptor antagonist for these reasons. findings, along with those from the present study, suggest
The present study demonstrates that the small molecule that renal I/R-induced increase in MPO and TNF-may
C5aR antagonist AcF-[OPdChaWR], has impressive tis- be due to activation of PMNs, monocytes and macro-
sue-protective effects against renal I/R-induced cellular phages by C5a following activation of complement. Inhi-
injury and renal dysfunction in the rat. Pretreatment with bition of the activation of these inflammatory cells by
this C5aR antagonist also reduced I/R-increased plasma the C5aR antagonist likely reduces I/R-induced renal
levels of creatinine and AST, hematuria, renal vascular injury through inhibiting production of proinflammatory
permeability, and markedly inhibited elevated renal tis- cytokines as well as leukocyte trafficking. Inhibition of
sue TNF- concentrations and renal tissue MPO activity these inflammatory cells also would result in the block-
caused by I/R. ade of both vascular leakage and leukocyte egress into
In other organs, C5a involvement in mediating leuko- the urine and interstitium.
cyte activation during certain I/R injuries has been pre- The increase in plasma creatinine after renal I/R may
viously demonstrated with C5a-induced sequestration of indicate impaired glomerular function [30]. Increased lev-
PMN in the coronary vascular bed [43] and in focal els of AST in serum or plasma usually denote liver dam-
cerebral ischemia [44]. Neutrophil infiltration into the age, but this enzyme is not only specific to liver, it also
kidney parenchyma in response to renal I/R injury is a is found in some other organs such as kidney and smooth
muscle. Plasma AST is regarded also as a marker of renalwell-known phenomenon and activation of these neutro-
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tubular damage [32] and plasma levels of this enzyme are insurmountable antagonist at both kinds of C5aRs [57].
The drug binds to rat PMNs with similar affinity to hu-elevated after renal reperfusion injury [31]. Pre-treat-
ment with the C5aR antagonist AcF-[OPdChaWR] re- man PMNs [54]. In rats, the plasma half-life for the drug
following oral or intravenous administration is approxi-duced plasma levels of creatinine and completely blocked
the I/R-induced rise in AST, suggesting that C5a is a mately 70 minutes [24], but the effect of the drug in
vivo is much longer than the blood levels would suggestmediator of injury to the glomerular and tubular cells.
The mechanism by which the C5aR antagonist reduces because of the insurmountable nature of its antagonism
at C5aRs [57]. For example, inhibition of C5a-inducedtubular and glomerular damage is not yet known. Recent
studies have shown that both glomerular and tubular neutropenia in rats, following a single intravenous or
oral dose, lasts for up to 24 hours after administration,cells express C5aR [40, 41, 48] and glomerular mesangial
cells are an important source of TNF- [49]. As C5a has when the drug is undetectable in the circulation [24]. We
attribute the long duration of drug action in vivo to abeen shown to produce TNF- in vivo [27], the C5aR
antagonist may be involved in inhibition of TNF- pro- slow off-rate from the receptor, so that drug levels in
the circulation are not necessarily relevant to therapeuticduction within glomerular and tubular cells.
In certain models of I/R injury in other species such effect or duration.
as the mouse, the MAC has been suggested to be a more Renal I/R injury remains a significant cause of patient
important pathogenic factor than C5a [50–52]. One study morbidity and mortality. Our study shows, to our knowl-
reported that neither C5a-mediated neutrophil infiltra- edge for the first time, that the first reported, orally active
tion, nor the classical complement pathway in which C4 small molecule C5aR antagonist is highly effective in
participates, appears to contribute to renal I/R injury reducing the renal dysfunction and tissue damage caused
in this model [52]. Other studies in C3-deficient mice by I/R in the rat. The results suggest an important role
reported only partial protection from renal I/R-induced for C5a in I/R in the kidney, and a potential role for C5aR
injury, and the use of a rodent C3a convertase inhibi- antagonists in the treatment or prevention of human I/R
tor (Crry-Ig) was ineffective, suggesting that other pro- kidney injury.
inflammatory mediators operate in parallel with comple-
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